Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $2.0 million with $1,000,000 previously funded on January 23, 2026, $675,000 funded with Scott M. Pittman and four other lenders at annual rate of 12% (increased from 10% on prior notes) maturing December 31, 2028.
- Instrument
- credit facility
- Principal
- aggregate principal amount of up to $2.0 million with $1,000,000 previously funded on January 23, 2026, $675,000 funded
- Counterparty
- Scott M. Pittman and four other lenders
- Rate
- annual rate of 12% (increased from 10% on prior notes)
- Maturity
- December 31, 2028
- Event
- incurrence
Exact text from the filing
On May 29, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (the “Interim Loan Agreement”) with five lenders (collectively, the “Lenders”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Nuo Therapeutics, Inc. issued shares of the Company's common stock of warrant to five lenders (collectively, the 'Lenders') for issued as loan fees and for accrued interest.
- Security
- warrant
- Shares
- shares of the Company's common stock
- Purchaser
- five lenders (collectively, the 'Lenders')
- Consideration
- issued as loan fees and for accrued interest
Exact text from the filing
On May 29, 2026, the closing date of the Interim Funding, and pursuant to the Interim Loan Agreement, the Company (a) issued to each Lender warrants, a portion of which are subject to vesting provisions, to purchase shares of the Company’s common stock, (b) cancelled certain warrants previously issued pursuant to the Initial Funding, and (c) again agreed to issue additional warrants to each Lender in the Interim Funding to purchase shares of the Company’s common stock as payment for accrued interest under the Notes.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Nuo Therapeutics, Inc. amended Amended and Restated Loan and Security Agreement with five lenders valued at $2.0 million (effective 2026-05-29).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- five lenders
- Value
- $2.0 million
- Effective
- 2026-05-29
Exact text from the filing
On May 29, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (the “Interim Loan Agreement”) with five lenders (collectively, the “Lenders”).
View on SEC.gov